<SEC-DOCUMENT>0000200406-11-000099.txt : 20111011
<SEC-HEADER>0000200406-11-000099.hdr.sgml : 20111010
<ACCEPTANCE-DATETIME>20110822103757
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000200406-11-000099
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20110822

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0209

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
<head>
    <title>augustseccommentletter.htm</title>
    <!-- Licensed to: Johnson & Johnson -->
    <!-- Document Created using EDGARizer 5.3.1.0 -->
    <!-- Copyright 1995 - 2011 Thomson Reuters. All rights reserved. -->
</head>

<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="TEXT-ALIGN: center"><img src="secletter4.jpg" alt=""></div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="42%">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stephen J. Cosgrove</font></div>
</td>
<td align="right" valign="top" width="48%">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One Johnson &amp; Johnson Drive</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="42%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vice President</font></div>
</td>
<td align="right" valign="top" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">New Brunswick, NJ 08933</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="42%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Corporate Controller</font></div>
</td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">August 22, 2011</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Via EDGAR</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ms. Tabatha Akins</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Staff Accountant</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U.S. Securities and Exchange Commission</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Division of Corporation Finance</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">100 F Street, NE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, DC 20549</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Re:&#160;&#160;&#160;&#160;&#160;&#160;&#160;Johnson &amp; Johnson</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Form 10-Q for the Quarterly Period Ended April 3, 2011</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Filed May 10, 2011</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dear Ms. Akins:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Johnson &amp; Johnson is submitting this letter in response to the verbal comments of the Staff (the &#8220;Staff&#8221;) of the Securities and Exchange Commission (the &#8220;Commission&#8221;), per discussions held on August 9, 2011 and August 11, 2011, with respect to Johnson &amp; Johnson&#8217;s Form 10-Q filed with the Commission on May 10, 2011 for the interim period ended April 3, 2011 (the &#8220;Form 10-Q&#8221;).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Set forth below is the comment followed by our response:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Form 10-Q for the Interim Period Ended April 3, 2011</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Part I, Item1</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Notes to Consolidated Financial Statements</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">11.&#160;&#160;Legal Proceedings</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Product Liability, page 18</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1. We believe the quantitative disclosure outside of the financial statements specified in SAB (Topic 5Y question 3: What disclosures regarding loss contingencies may be necessary outside the financial statements?) should be made related to aggregate claims related to product liability such as aggregate settlement, disclosure of the number of claims pending at each balance sheet date, the number of claims filed for each period presented, the number of claims dismissed, settled, or otherwise resolved for each period, and the average settlement amount per claim.&#160;&#160;We also believe that historical and expected trends in these amounts and their reasonably likely effects on operating results and liquidity should also be disclosed pursuant to the SAB.&#160;&#160;Please provide proposed disclosure.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on our discussion the disclosure should address material matters.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Response:</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; BACKGROUND-COLOR: #ffffff">In response to the staff&#8217;s verbal comment and request for information the Company will enhance disclosure related to product liability in future filings beginning with Form 10Q for the period ended October 2, 2011 as follows:</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">PRODUCT LIABILITY</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s subsidiaries are involved in numerous product liability cases. The damages claimed are substantial, and while the Company&#8217;s subsidiaries are confident of the adequacy of the warnings and instructions for use that accompany the products at issue, it is not feasible to predict the ultimate outcome of litigation.<a name="eolPage23"><!--EFPlaceholder--></a> The Company has established product liability accruals in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. Changes to the accruals may be required in the future as additional information becomes available.&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Multiple products of the Company&#8217;s subsidiaries are subject to numerous product liability claims and lawsuits. There are a significant number of claimants who have pending lawsuits or claims regarding injuries allegedly due to ORTHO EVRA&#174;, RISPERDAL&#174;, LEVAQUIN&#174;, DURAGESIC&#174;/fentanyl patches, pelvic meshes, the CHARIT&#201;&#8482; Artificial Disc, CYPHER&#174; Stent, and ASR&#8482; Hip. These claimants seek substantial compensatory and, where available, punitive damages.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In August&#160;2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">There are approximately xxx claimants who have filed lawsuits, which are currently pending, regarding injuries allegedly due to the DePuy ASR&#8482; Hip.</font>&#160;&#160;The Company has received limited information to date with respect to potential costs associated with this recall. The Company&#8217;s product liability accrual has been increased in part due to an increase in<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font>anticipated product<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font>liability<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font>litigation&#160;settlements<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font>and costs associated with the<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>DePuy ASR&#8482; Hip recall<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>program.&#160;&#160;Changes to the accruals may be required in the future as additional information becomes available.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><a name="eolPage24"><!--EFPlaceholder--></a>The Company believes that the ultimate resolution of these matters based on historical and reasonably likely future trends is not expected to have a material adverse effect on the Company&#8217;s financial position, annual results of operations and cash flows.&#160;&#160;The resolution in any interim reporting period could have a material impact on the Company&#8217;s results of operations and cash flows for that period.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As requested, we acknowledge that:</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Johnson &amp; Johnson is responsible for the adequacy and accuracy of the disclosure in the filing;</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Johnson &amp; Johnson may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Please do not hesitate to contact me at 732-524-1831 with any questions or comments you may have.</font></div>

<br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;Sincerely,</font></td>
</tr><tr>
<td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="50%">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>

<div>&#160;</div>

<div>/s/ Stephen J. Cosgrove</div>

<div>Vice President</div>

<div>Corporate Controller</div>

<div>Chief Accounting Officer</div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><br>
</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;Copy:</font></td>
<td width="95%">
<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Joel Parker, Accounting Branch Chief</font></div>

<div>Jim B. Rosenberg, Senior Assistant Chief Accountant</div>
</td>
</tr></table>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>secletter4.jpg
<TEXT>
begin 644 secletter4.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!<`=L#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#VW3]/LCIM
MJ39V^3"G_+)?0>U6?[.L?^?.W_[]+_A1IW_(,M/^N*?^@BN(\>>-)K"4:'HS
M%M0EPLDB<F/=T5?]H_I4RDHJ[.C#8:>)J*G#_AO,UM:\0^'M&N!9BS2\OVX6
MTM8`[Y]_2F>%-9L_$YO@VAQ69M)`A#JK$DYR#P,$8JE:Z3;^`?!UYJ4H6756
MBS),W),C<!0?0$_CUIWPKMS'X6EN7R9+FZ=V8]3C`_F#6:E)R29W5,/AXX6<
MX*]FDI=WULNUO4Z_^SK'_GSM_P#OTO\`A1_9UC_SYV__`'Z7_"K-%;'DE;^S
MK'_GSM_^_2_X4?V=8_\`/G;_`/?I?\*LT4`5O[.L?^?.W_[]+_A7*Z[XN\,:
M#>&SDM$N;E?OI;P*=GU)P,^U;7BK6/["\-WE^N/-5-L0/=VX'\\_A7GWPOT^
M.\FUC4KH"614\L,_))?)8_4\?G64YNZC$]/!X2G*C/$UM8QTLNK_`*9Z#HMS
MHFOZ<M]86T#1$E2&A4,K#J".QK0_LZQ_Y\[?_OTO^%>>_"`G['JRY.P2QX'O
M@_X"O2ZJG+FBFSGQV'CA\1*E'9?\.5O[.L?^?.W_`._2_P"%']G6/_/G;_\`
M?I?\*LT59R%;^SK'_GSM_P#OTO\`A1_9UC_SYV__`'Z7_"K-%`%;^SK'_GSM
M_P#OTO\`A1_9UC_SYV__`'Z7_"K-%`%;^SK'_GSM_P#OTO\`A1_9UC_SYV__
M`'Z7_"K-%`%;^SK'_GSM_P#OTO\`A1_9UC_SYV__`'Z7_"K-%`%;^SK'_GSM
M_P#OTO\`A1_9UC_SYV__`'Z7_"K-%`%;^SK'_GSM_P#OTO\`A1_9UC_SYV__
M`'Z7_"K-%`%;^SK'_GSM_P#OTO\`A1_9UC_SYV__`'Z7_"K-%`%;^SK'_GSM
M_P#OTO\`A1_9UC_SYV__`'Z7_"K-%`%;^SK'_GSM_P#OTO\`A1_9UC_SYV__
M`'Z7_"K-%`%;^SK'_GSM_P#OTO\`A7.ZUXB\/:/<BR6R2]U`\"TM8`[Y]_2L
MGQWXSGM)QH.BL6OY2%DD3DQENBK_`+1S^'\IH=+MOA_X+O+]MLFJO'\\YY+2
M-P%!]`3^.,UE*=VU'H>G1P2C",ZVKG\,>_F^R_,O^$]9LO$ZWI.AQ6AM9!&0
MP5B20<]A@C%='_9UC_SYV_\`WZ7_``KD?A9;>5X2:X;E[FY=RQZG&%_H:[>J
MIMN*;.?'0A3Q,X4U9)V*W]G6/_/G;_\`?I?\*/[.L?\`GSM_^_2_X59HJSD*
MW]G6/_/G;_\`?I?\*/[.L?\`GSM_^_2_X59K%\6ZR="\-7E\A'G!=D.?[[<#
M\NOX4F[*Y=.G*I-0CN]#&UWQ?X8T*]-G)9K<W"?ZQ+>!3L]B3@9]JVM&N-$U
M[3DOK"W@>)B00T(#*1U!'8UY]\,=.BNEUK4;E1*XC\H,XS]X$N?J>*T/@^S_
M`-G:HN3L$R$#WVG/\A6,*DFU?J>QB\!0I4JBA?FI\MWWOY=#T'^SK'_GSM_^
M_2_X4?V=8_\`/G;_`/?I?\*LT5N>(5O[.L?^?.W_`._2_P"%']G6/_/G;_\`
M?I?\*LT4`5O[.L?^?.W_`._2_P"%']G6/_/G;_\`?I?\*LT4`5O[.L?^?.W_
M`._2_P"%']G6/_/G;_\`?I?\*LT4`5O[.L?^?.W_`._2_P"%']G6/_/G;_\`
M?I?\*LT4`5O[.L?^?.W_`._2_P"%']G6/_/G;_\`?I?\*LT4`5O[.L?^?.W_
M`._2_P"%']G6/_/G;_\`?I?\*LT4`5O[.L?^?.W_`._2_P"%']G6/_/G;_\`
M?I?\*LT4`5O[.L?^?.W_`._2_P"%']G6/_/G;_\`?I?\*LT4`8=_JRZ)X..H
ML`3#:J44_P`3$`*/S(KS/X;V#ZSXPEU&[)E:V4SLS<[I6.`?YG\*Z+XCSM'X
M%TN$=)9(MWT"$_SQ3?A#$!IVJ3?Q-,B?@%S_`%KGE[U5(]_"Q]AEE2LMY:?+
M;_,7XN7Q33M/L%;_`%TK2N/91@?JWZ5O_#M`O@;3L?Q!R?\`OMJX?XM2%O$-
MC'GA+7./JQ_PKM?AQ)YG@>Q']PR+_P"/FB+O588FGR933MU=_P`SJZ**YZ?Q
MMH<6JPZ9%<M=7<L@C"6R&0*3ZD<?7TK=M+<\2G1J5+\B;L=#17,S^/\`PW;:
MBUE)J`WJVQG",44^A8#%=)'(DL:R1NKHPRK*<@CU!H4D]AU*%6FDYQ:OM='G
MWQ<N"FAV%N#Q+<[B/7:I_P`:R?!5^FE?#[Q!>DX97*K[L4`4?F:O_%__`(\]
M)_ZZR?\`H(KC_#5I>^(8X_#<`*6C7/VJZE'90`!_7'N1Z5RS;530^FPE*,\M
MCS.RO=^B?_`/1/A=IK6/A,7#KA[R4R#_`'1\H_D3^-=M65J.JZ5X6TJ)KJ5;
M>VC`CB11DG`X"COQ3=!\2Z;XDMY)=/E8^4VV1)%VLN>F1[UT1M%*)X&)]KB)
M2Q/*^5O?H:]%%<M=?$+PY::F;%[MV</L>5(R8U/3EO\`"J<DMS"E0J5FU3BW
M;L=312`@@$'(/0BN>UOQOH>@W@M+N=VN,`LD*%R@/KZ?3K0Y):L5*C4JRY:<
M6WY'145#:7<%_:17=K()8)5#HZ]"#5;6M6M]#TBXU&ZW&*%<E5^\QS@`>Y-%
MU:XE3E*?(EKM;S+]%0VES%>V<-U`VZ*9`Z'U!&14Q(`))P!U-,EIIV845S6I
M^/O#FENT<E^)I%ZI;J9,?B./UI;SQSH6GVUK+=SRQ-<QB5(3$3(%/0LHZ?C4
M\\>YT+!XAVM!Z[:'2453TS5;'6;-;O3[E)X2<97J#Z$=0?K3-6UG3]$M/M.H
MW*01]!GDL?0`<DT[JUS'V4^?DL[]NI?HKGM"\::-XANWM;*603JNX)+&5+#N
M1ZUO2RQP0O-,ZI&BEF=C@*!U)H335T.I1J4I<DXM,?17,Z=X^T#5-573[:YD
M\USMC9XRJ2'T!/\`6NFH4D]AU:-2B[5(M/S"BBBF9!67XBU==#T"\U`@%HD_
M=J>[GA1^9%:E<!\6KAH_#MI`#Q+=#/\`P%2:F;M%LZL%15;$0IO9LYCX:Z>^
MK>+)M2NB93;*9F9N=TKG`/\`Z$:W?B[?%++3M/5N)9&F<>RC`_5C^5/^$4(7
M2M2FQR]PJY]@O_US6'\69=_B:TB[1V@/YLW^%<^U+U/H+^US>SVBM/N_S9WG
MP^4+X&TS'=&)_P"^VKIJY?X=R"3P-IV/X`ZG\':NHZ#)KHA\*/G\;_O-3_$_
MS"BN>E\:Z&FK0Z9#<M=7<L@C"VR%PI]R..._I44OC_PU!J#6;Z@-ZML9PC%`
M?3=C']*.>/<2P>(>T'WV>QTU>=?%VX9-'TZW!^62X+'_`("O_P!>O1$=9$5T
M8,C#*LIR"/6O-/B__P`>VD?]=)?Y+4U?@9TY2KXV"?G^3*7@Z_72OAOK]X2`
MWF,B>[%%"_J:Z7X8::UCX12=UP]W(91_N_=7]!G\:\Z\,V=[XCCA\.0@I9?:
M3=W<H[+@*!^AQ[GVKV34]7TOPQID;W<JP6Z`1Q1J,DX'`4=^*SI?S/9'HYI>
M+E0AK*<KV79*R7ZFK163H/B/3?$EM)/I\K-Y;;9$==K*>V16M6Z:>J/GZE.5
M.3A-6:"BN6N/B'X<MM3^PO=LS!]C2I&3&IZ<M_45U(((R.10I)[%5*%6DDZD
M6K[7"BN<UKQQH>A7OV.[N':<8WI"A?9G^]Z?3K6[:W4%[:175M(LD$JAT=>A
M!H4DW9!.A4A%3E%I/9DU%9^MZQ;Z#I$^HW08Q0@?*GWF).`![U;MKB.[M8KF
M%MT4J!T/J",BBZO8GDER\]M-B6BD)`!).`.I-<UJ7C[PYI;M')?B:1>JVZF3
M'XCC]:')+<JE1J57:G%M^1TU%<W>^.="TZ"VDNYY8GN(Q*L)B)D53T+`=/QK
M8TW5++6+-;NPN$GA8XW+V/H1U!]C24DW9,<\/5A'GE%I=[%RBJ&K:UI^AVGV
MG4;E88R<+GEF/H`.36=H7C/1O$5R]M8RR"=%W>7*FTL/4>M/F5[7".'JR@ZB
MB^5=>AT%%,FFBMX'FFD6.*-2SNQP%`ZDUSFF^/=`U755T^VN9/-<XC9XRJR'
MT!/]:')+1BIT*M2+E"+:6YTU%%%,R/.OB-;M)X$TV8=(9(B?H4(_F14?PAF!
ML=5@SRLR/CV*X_I777VE)K?@XZ<Q`,UJH5C_``L`"I_,"O,/AYJ#Z'XQ>PO`
M8C<`VTBM_#(#\OZY'XUSR]VHF>_A7[?+*E%?%'7Y;_YEKXM1E?$5C)V>UQ^3
M'_&N@^&NI6UGX'N)KN9(8;:Y?>[G@`@'^M4_B];9MM*NP/NR/$3]0"/_`$$U
MR_@OP[<^*)I+.2Y>+2K>19IT5L%F(P,#UP.O:I;<:KL=D(4Z^50]I*R6_P`F
M_P`2YXM\;:EKL#BQ2:UT;S/*W]&F;&<$_3^$?C6M\)]&BDCOM5=1Y@/V>$_W
M.,L1[\BCXIV,.GZ3HEM:0K#:Q/(JH@P`<#']:O\`PDO8WT2]LLCS8KCS,=RK
M`8/YJ:$OWMI$UIQ_LMRH1Y4W\[7MKYLXL6-GX;N-0TWQ-I$\GFG]Q>0]4QGY
MES@$'@_H:T/"/CVXT/2GTT6,VH$/FV"'&U3U!X)QGGCUKV5XTE7;(BNOHPR*
M\S\$M'<?$KQ!<6P'V?$@4J./O@#'Y&FX.$E9F<,=#%T*CK0ORI-ZNU]M.U_(
MYKQE?^)-3AM+O6[,6=LSL+:#;M(.!DD'GICK^5==\)O+CT'4I6VKBX^9SQP$
M'4^G6HOB_P#\>>D_]=9/_017(Z/JLZ^%IO#^GY-_J=X$P.T>T`\^YX^F:EOD
MJ:G2H_6\NC&*44WTV23W_4G\67MYXH>\UY#MTJSE6UMPW\6>I'OT)^H%:OPB
M8_VUJ2YX-NI(_P"!5L>-=(@T+X9PZ=!]V*6(,V/OMG)8_4US_P`,+R#3[[5[
MRYD$<$-H'=CV`:BUJBN)U(ULMJ*FO=3LO2Z_%G;^/?$3Z/I*V5D2VI7Y\J%4
M^\H/!;Z\X'N?:O%M4TZ?2;^XT^YV^=!\K[#D9P#U_&O4?!]G/XI\17'B[44(
MA1C'8Q-T4#C/X?S)]*X3QUSXTU;_`*Z#_P!!%*K>2YB\I4:%1X9;I7D_.ZT^
M7YGK-[K\?A[P):ZC*0TOV6)8E/\`'(4&!_4^P->,ZU8WUE>I)J3[KJ\B%T^>
MHWD_>]^*[C3/^*V\1Z7:\MI&C6T9D]))-HX_,8^BGUK*^*?_`"."_P#7JG\V
MIU/>C?H1EL5AZ_L?M23;\ET7ZL]`^'+$^!K#)S@R`?3>U<=\4O$`NKV/1+=\
MQ6Q$EP1T+GHOX`_F?:M31/$47AKX56UVQ4W#&1((S_$Y=OT'4U!8Z)9Z-X"U
M/4_$6YKO4TW/G[X)Y11_M9^;_P#55-W@HKL<M*$:6+GB:BO[[45W=]7\E^)#
MX"\;6>EZ!<V6JS[%M/G@[LZD_<`[D']#[4^YEUWQK9SZA>2OI'AN)&DV+_K)
ME'/X]/I]:\]T=H(]:L&O(5EMQ.GFQMT920#7N?C6-O\`A"-52$8Q;G``Z`8S
M^E*#<HZ[(WQT*>&Q494X^]4>[Z=[+OUN>1^!])@UGQ=:PR1YMH]T[(W.0O0'
MUY(S72>-M-;3/&R:Y?::VH:3,JB1!G`(7;@^GJ,\&LCX9WD=KXRC20A?M$+Q
M*3_>X8#_`,=KV\C(P:*<%*!&9XR>&QJ=KKEM;;1[Z]'YGA6E^)5T#Q'<3>'+
M>>2TNU"):7'7>>@X)S@].^#BMW4/"&L:IH]_X@\2WSK=Q0-)#;)C"`#.#V'T
M'XFK/CHQS^/_``[9VX42HZ,P4=,R`C/X*37<>*O^13U?_KTE_P#033C"]T^@
MJ^,<71J4XVE.UV]79.V_F>._#UB/'.G8.,^8#_WPU=OX]O[K6-3MO"&EL/.G
MQ)=-G`5>H!]NY_#UKSOPIJ<&C^([;4+C/EP+(V!U8[&`'XD@5Z5\/=+FDMKS
MQ+J`W7NI,S*3_#'GM]3^@%33UCRHZ<S2I5_K4E\*27G*[_+<\HTLM'K=B5.&
M6ZCP1_OBOI.OFS3O^0W9_P#7W'_Z&*^@[[6]/TV\L[.ZN52XNWV0QX)+'\.@
M]S54'9.YS<00E.=-15W9FA03@$XS["O&OB)XBUA/$USI\=U/;6L"KLCB<IOR
MH.XD=>?Y5LV7ACQ);Z1!J>B>*);J5XQ)Y$A+1OQG`))'YC\JOVMVTD>>\KY:
M4*E2HH\VV_XOH7]+^(YU'Q:FDR:<;6"1VB#2-^\$@Z`CH.F,4GQ9MS)X;M9P
M/]3=#/L"I'^%>?SZK+>>-;/4)[86=X+B(7"?=`D5@"<'IG'(KU+Q5JWAW4]$
MO-+GUFQ225,(?-!VN.5)Q[@5"ES1:;.ZMAEA<51J4H675+7U_,P_A#,#INIP
M9Y6=7Q[%<?\`LM8OQ9BV>)K27M):`?DS?XU5^&>K+IOBC[+,P$=ZGE9SQO!R
MOY\C\:WOB];?N]*NP.C21$_4`C^1I7O2]#?E=+.+O:2_3_-&A\.-4MK+P)-/
M>3I%#:W$@=F/`!P?ZURGBWQKJ>O0/]B2:UT8R&(-T:9L9PQ^G\(_&JO@OP[<
M^*)'LY;IX])MI!-/&K8+.1@8'K@=>U=!\5+.&QTW1+>UA6*UB:151!@#A?\`
MZ]*\G3\BHT\/3S'E?O3DV_*.E_O?X#OA3HL<EK?ZHZXD)-M"W]P8RQ'YC\JY
MA;&R\./?Z9XFTBX=I#^XO(NJ8S\RYP"#P?T-=O\`"6\CDT"[L@1YL-P7(_V6
M`P?S!KOWC25=LB*Z^C#(JXTU*"L<>)S">'QE6,U=.W6STVLSQOPEX^N=%TAM
M,^PS:@ZOFV"-]U3V/!.,_P`ZH^,K[Q)J4=G=ZY:"SMV9A;0;=I!P,D@\^G7\
MJZ;P*R7/Q%\0W-MC[-API4<8,@QC\C3OB_\`\>ND?]=)?Y+4--T[W.R%6E',
M8PC32E+5OKJK_(L_"<QQ>&]0F?:@%R2[GC@(IY/H.:X_Q9>WGB=KKQ`/ETNV
MF6TME;JV<DD?ED_4#M4>D:I.WA1_#FGY-]J=]M8#^&/:H_4C\@:['QWI,&B?
M#BTTZW'R0W$8+8Y9N<L?J<T?%"W1!94,=SR^*<K+RCU?SV7S,OX1,?[6U1<\
M&!#C_@1KJ_'WB&32M+33K$EM2U`^5"J?>4'@M]><#W/M7%_#"]M]-N=:O;IP
MD$-JKNQ]`QK>\&V5QXFU^X\7ZE&0@8QV,3=%`XR/IT^I)JH/W%%;LY\=2BL;
M/$55[L;?-VT7^?D>6ZGI\NE7US87&SSH#L?8<C.,\?G7N6J>((_#O@F"_<AI
MC;QI"A_CD*C'^)^E>0>->?&.L#_IN?Y"NRTW_BM_%-A$,OH^C01ELCB23`_J
M/R4^M1!\K:1V8^FJ]*E5J_"ES/[EI\WH<'K5A?6%\IU%]UU<Q+<OGJ"^3@^]
M>S_#TD^!M-R?X7'_`(^U>=?%'_D<C_U[1_S-=/I?B./PU\*K&ZR#<NKI;H?X
MGWMS]!U-.G:,V99ASXK!4N5:R:_)F1\4?$/VR_CT6W;,-J=\Y'0R'H/P!_,^
MU6?`GC>STOP[<V>JSE19_-!W9U/\`'<@_H?:I+71+/0_A]J6H>(=S7FIIN?/
MWPQY11_M9^8__6KSW0VMTUW3S>0K+;_:$$L;#@@G']<TG*49<W<UHX?#U\)*
M@DW&#W75K>WXKT._NI-<\9V4^I7\SZ3X<A1I!&GWYE`S^/X\>@-<OX$TF'6/
M%UM%+'FVA#3LC<Y"_=!_$BO6/'"-_P`(/JJQ#&(.@[`$9_2O-/AA>1VOB]8Y
M"!]I@>)2?[W#`?H:J<;329AA*\IX&M.FN5*Z2733?S?F:GC33FTOQP-;U#3'
MU#29E7>HS@$+MP?0C&1G@UAZ5XE_L#Q%<R>&[>>6TNP$CM+CKO/3H3G!R!W(
M->ZD9&#TKS#QF8YOB3X>M;<+YD;1EPHQC+Y_D,TZD.7WDS#`8U5U["I"Z4;;
MZ66JNN_F5=3\'ZOJ&BW_`(@\27SB]CA:2&V3!"`<X/8?0?G6'\."?^$YL?=)
M?_0#7KGB[_D4-6_Z]7_E7B?A+58-$\0Q:C<9*0Q2D`?Q,4(`_$XJ9Q49HZL#
M7JXK!UDUW22Z:;(]"\>7]UK>JVWA#2V'F2?O;IB>%4<@'V[G\*\QT9FCU_3B
M#AENX^?^!BO5OA[I4QLKOQ'J'S7VIEG!/\,>?ZG]`*\ITK_D/V/_`%]Q_P#H
M8J:EW:3ZFV7N$(5,/#:"5WW;O?\`R^1](T5GWNMZ?IU]9V5S<JES=OLACP26
M/X=![FM"NRZ/CG"44FUN5M._Y!EI_P!<4_\`017%>/\`P4^I@ZSI2D:A$`9(
MTX,H'0C_`&A^OY5VNG?\@RT_ZXI_Z"*YOX@Z^^C:!Y%J3]MOCY,.WJ`?O$?G
M@>Y%342Y7<Z\NG6CB8^QW?W6ZW\CS;6_$>L>+-)C62'%OIL:O=.O1G)VACZ=
M>GUKH/A"Q%]JJ=C'&?U:MQO"\>B?"_4+':#<O;--._JX&<?08P/I6%\(%)OM
M5?'RB*,?JU<ZBU-7/>K5Z57`5HT5:,79?>M?O.Y\8>'_`/A(_#TMG&0+A")8
M">F\=C[$9'XUXA97^J>%]8,D.^UO8LI)'(O4=PP[C_(KZ-JE?Z1INJ`"^L;>
MXQT,L88C\:VJ4N9W6YY67YG]6@Z-2/-!GD5[\1_$.LV_]GVT$,,LWR'[*C&1
M\]ADG%=]X"\+OX;T=FN@!?71#R@<[`/NKGVYS[FMZPT;3-,S]AL+:W)ZF.,`
MG\:O40IM.\G<G%X^G.G['#PY(O?NSS7XO@_8M)../.DY_P"`BJOPIT#S)I]=
MG3Y4S#;9'4_Q,/Y?G7I=]I]GJ=N;>^MHKB$G.R10PSZU+!;PVL"06\211(,*
MB+@*/84>SO/F8UF3C@?JL5KW\KW.1^)Z,_@N8JI(2:-FQV&>OZUY9X8T>\\0
M:I_9=M(Z6\NUKIEZ"-3G)_'I[U]!2Q1SQ/%-&LD;C#(XR"/0BJ^GZ58:5&T=
MA9PVR,<L(D"Y/O2G2YI7+P>:_5L-*DH^]>Z?]=B6SM(+"SAM+:,1P0H$11V`
MKP;QR"/&^J@@Y\U<#'7Y17O]49M&TRXU!+^:PMY+M,;9FC!88Z<U52GS*R,<
MNQZPE652:O=?\$R?`^@?V!X;ACE3%U/^^G]0QZ+^`P/SKSSXJQNGBV)V4A7M
M5VGUPS9KV>J>H:5I^JHB7]G!<JARHE0-M/M2E3O'E083,'2Q3Q%17O>_S/*/
M`7AZY\0W-K=:@6;2=.)$$;#Y7<G<0/49Y)^@K:^*S,)=#%P'_L[SF,VWN?E_
M7;NQ^->C0PQ6\*PPQI'&@PJ(N`![`5'=V=M?V[6]W!'/"W5)%#`_@:7LK0Y3
M26:.6+5>4?=5[+M?]>IXH;2+Q;\1'_LF,_8FF1V<+@+&H&6QVSCBO;KB".ZM
MI;>9=T4J%''J",&H;'3+'2X3%8VD-M&>2(D"Y^OK5JJA#EO?J8X[&_6'!05H
MQ5EW]3YXU_0;[PMJY@EWJJONMKA>`X!X(/8CTK?A^*FO0V0A>.SEE`P)W4AO
MJ0#@FO8[FUM[R$PW,$<T1ZI(H8'\#6?;>&-"M)O-@TBS20'(80C(^GI6?L9)
M^ZST7G%"M32Q-+FDOZ^1PO@+P]J.HZTWBC6?,+'+0^:,-(Q&-V.R@<#_`.M7
M<^*%+>%-65023:2\#_=-:U(0&4JP!!&"#WK6,.6-CRJ^-E6KJK)62M9=DNA\
MZ>'='DU_7+73X\[9&S*P_AC'+'\N/J17T1'!'!;I!$H2-$"(HZ``8`JM8:/I
MNEF0V%C;VQD.7,484FKM33I\BU-\SS'ZY-<JM%'S3*L^FZK(KKLN+6<DAAT9
M6SS^5>F^`]*OM;U:3Q9K1:20_+:AA@>A8#L!T'U)KN+S0-(U"Y6YO--M9YA_
M')$"?Q]:T%544*H"J!@`#``J84;.[9U8S.57I<L(VDU9ORZI>IC:]X5TGQ&B
M_;X#YJ#"31G:ZCTSW'L:Y=?A<;4D6'B._MHR<[5'^!%>A45HZ<6[M'FT<?B*
M,>2$M.V_YGBVN>#ET[Q9HVGR7D]\=0<><\O#$;@#SUZ9KTRV\&>&[1-L6C6A
M]W3>?S;-:TEG;37<-U)!&]Q""(I&4%D!ZX/;-3THTDFS;$YE6K0A'F:LM>EW
M?R\CSGQIX`C:!=2\/VZP7,'S/!"-N\#G<OHP_6N.UWQ'J_BW2XS)#BVTV-6N
M67HTA.T,?3.>!]:])^(6O2:1H(M;4G[=?MY,07J!_$1[\@#W-4KCPQ'HGPMU
M"P"@W#6YFG<?Q2#!_(8P/I64X7;4?F>G@\6X4:<ZZN^:T6][?:?^7F8WP@D_
MTG5H_5(F_5J[3QEX?/B/P_):Q;1=1D2P$]-P[?B"17%?"!";O5I/X0D2_CEC
M7JM722=.S.3-:LJ68.I#=6_)'SG8:CJGA?5S)`7M;R+*212+U'<,.X_R*Z&^
M^(OB'7(/[-MH(H9)_D/V56,CY[#).*]>O]'TW5`/MUC;W&.AEC#$?C18Z/IN
MF9^PV%O;D]3'&%)_&I5&2T3T.BIG&&J6J3HWFON,+P'X8;PWHS?:0/MMR0\P
M!SL`Z+^'/XDUSWQ?_P"/72#V\R0?H*]+JM?:=9ZG;_9[ZUBN(LYV2J&&?6M)
M4_<Y4>;0QTHXM8JIJ_\`@6/-OA3H&YY]=G3A<PVV1_WTP_E^=;OQ2C=_!I95
M)"7,;,?0<C/YD5V,$$5M`D$$211(,*B#`4>PI9H8KB%X9HTDB<;61QD,/0BA
M4[0Y2JF8.>,6):V:T\D?/WA?1KOQ!JG]F02/';2;7NV7H$4Y&??/3W^E>_6E
MK#96D5K;QB.&)`B*.P%16&EV&E1-%86<-LC'+")`N3[U;HIT^1#S+,'C)JRM
M%=/U9\^^-`5\::L"#DS\#')R!BO8/!.@_P#"/^'((9%Q=3?OISWW'M^`P*U)
M=&TR?4$U"6PMWO$QMF:,%ACIS5ZE"ERR<F:8S,_K&'A0BK)6OYV/%OBG&R>+
MU=@0LEJA4^N"0:L>`?#]UX@N;6]U$LVEZ;E;:-A\KOG=@#N`3DGOP*]5U#2=
M/U5$6_LH+D(<KYJ!MOTJS%%'!$L4,:QQH,*B#``]A4^Q]^[-7F[6$C0A&TDK
M7_R\['G'Q38B]T(78?\`LSSB9MHZG*Y_';NQ^-<Q'9Q^+/B.YTN,_8C.DK.%
MP%C4#)QVSC@>]>U7=E:W]NUO>6\<\+=4D4,#^=,L=-LM,A\FQM(;>,\E8D"Y
M^N.M.5+FE?H3A\T5##J$8^\DTNVKO?U);FWCN[6:VF7=%*A1QZ@C!KY\US0[
M_P`+:OY,N]-C[K>Y7@.`>"#Z^U?1%0W-K;WD)ANH(IXCU21`P_(U52GSF&79
MC+!R=U>+W1X[%\5=>BLA"\=G)*!@3LAW?4@'&:VO`'AW4+[6'\3ZR)"[9,'F
MC#.Q&-^.P`X'_P!:NYMO#.AV<WFV^DV<<@.0PA&1]/2M6IC3=[R=S?$9E1Y)
M0PM/EYMWUMV,?Q8I;PCJP4$G[+)P/I7AGAO1G\0:[:Z>F?+<[IF'\,8^\?Z?
M4U]%,JNI5@"I&""."*IV&D:;I>_[!8V]MYARYBC"YISI\TDR,#F?U2A."6KV
M992%(K=88E"(B[%4=``,`5\VMY^FZHVY=EQ:SY*L/NLK=Q^%?2U9UWH&D7]T
M+F[TVUGG'_+22($_CZT5*?/:PLLS&.$<^>-U+^OU.(\!:3>ZQJDOBW629)7^
M6UW#`]"P'8`<#\37I%(JA5"J`%`P`.@I:N$>56./%XEXBISM66R79=BMIW_(
M,M/^N*?^@BO/96_X23XOI$WS6NE)G';<O/\`Z&P_[YKT+3O^09:?]<4_]!%>
M;?#*3[3XJUZZ<YD?)Y]Y"3_(5%35I'5@%RTJU9;J-OOT.[\4RK#X4U9VZ"UD
M'YJ17)_".R,6AWMXP_U\X1?HH_Q)K0^)NI?9/"QLDYN+Z1840=2,@G^@_&M[
MPUI0T3P[96!QOCC'F'U<\M^I-%KU/0:E[++FG]N7X+_@FK1116IY84444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`>:;O\`A)/B_M;YK;24.!VW+_\`9M_X[79>+9!%X1U9VZ?97'YC%<-\+G^T
M>(]>N7.97YS]78G^E;OQ.U'[-X9%A'\UQ?RK$B#J0""?Z#\:PB_<<NY[N(I-
MXZEAUM'E7ZME/X2V1AT"[NV'_'Q<;1[A1C^9->@UF>'=+&B^'[+3^-T,8#GU
M8\M^I-:=:05HI'F8ZLJ^(G46S?X=`HHHJSE"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`K:=_R#+3_KBG_H(KP^>[U/P+XQ
MO#;@(^]P%D7*2QL<CZ]NG<5[CIXQIMJ/^F*?R%226\,S*TL4;E>5+*#CZ5G4
MAS6LSOP&-6&<E./-&2LT>=^%M+U;Q1KD7B;Q`NV&`?Z)`5V@GU"]@.N3U./2
MO2***J$>5&.*Q+Q$[VLEHDMD@HHHJCF"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#P5[S4_`GBZ\\C"R!V4+
M*N5EC)R#[]NE=GX5TK5?$NN1^)_$"E8X1_H<!7:,_P!X+V`Z\]3SVKT.2WAF
M96EBC=E^Z64$CZ5)6,:5GJ]#V,1FWM8>[!*;5G+K;R]0HHHK8\<****`"BBB
L@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
